PEAK, NCT05208047: (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
|
|
| Recruiting | 3 | 426 | Europe, Canada, US, RoW | CGT9486 plus sunitinib, CGT9486, Sunitinib, sunitinib - Part 1b, sunitinib - Part 2 | Cogent Biosciences, Inc. | Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | 07/25 | 09/26 | | |
